Latest post
Professor Alan Stitt: Researching the AMD pathway
An interview with Alan Stitt about research in the AMD field.
science community
A strategic focus for Oxurion: researching and developing non-VEGF pathways
Jean Feyen, PhD., Chief Scientific Officer, and Andy De Deene, M.D., Global Head of Development, explain why Oxurion decided to focus on non-VEGF pathways.
back of the eye diseases, science community,
Research opportunities for treating age-related macular degeneration
Age-related macular degeneration (or AMD) is the leading cause of blindness. At Oxurion, we’re discovering new ways to treat both forms.